A large B-cell non-Hodgkin lymphoma arising in the mediastinum. Morphologically it is characterized by a massive diffuse lymphocytic proliferation associated with compartmentalizing fibrosis. Response...
Comprehensive, easy-to-understand information about this condition
How we create this content →The limited documentation surrounding primary mediastinal large B-cell lymphoma is largely due to its rarity, affecting fewer than 10 individuals per 100,000. This low prevalence restricts the number of systematic clinical studies and comprehensive data collection. Additionally, the lack of established genetic factors and inheritance patterns complicates the understanding of the disease, contributing to the gaps in clinical knowledge.
To navigate your care effectively, seek out a hematologist or oncologist with specific experience in lymphomas, particularly those specializing in primary mediastinal large B-cell lymphoma. Consider participating in clinical trials, as they may provide access to cutting-edge treatments. You can find relevant clinical trials at ClinicalTrials.gov. For additional support, you may explore resources such as the Genetic and Rare Diseases Information Center at rarediseases.info.nih.gov, which can provide guidance on available options and potential registries.
There are currently 85 active clinical trials investigating various aspects of primary mediastinal large B-cell lymphoma. Among the drugs designated for this condition, axicabtagene ciloleucel, lisocabtagene maraleucel, and pembrolizumab have received FDA approval, while nivolumab is still in development. For more information on ongoing trials, you can visit ClinicalTrials.gov and search for primary mediastinal large B-cell lymphoma.
Actionable guidance for navigating care for primary mediastinal large B-cell lymphoma
To navigate your care effectively, seek out a hematologist or oncologist with specific experience in lymphomas, particularly those specializing in primary mediastinal large B-cell lymphoma. Consider participating in clinical trials, as they may provide access to cutting-edge treatments. You can find relevant clinical trials at ClinicalTrials.gov. For additional support, you may explore resources such as the Genetic and Rare Diseases Information Center at rarediseases.info.nih.gov, which can provide guidance on available options and potential registries.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding primary mediastinal large B-cell lymphoma is largely due to its rarity, affecting fewer than 10 individuals per 100,000. This low prevalence restricts the number of systematic clinical studies and comprehensive data collection. Additionally, the lack of established genetic factors and inheritance patterns complicates the understanding of the disease, contributing to the gaps in clinical knowledge.
To navigate your care effectively, seek out a hematologist or oncologist with specific experience in lymphomas, particularly those specializing in primary mediastinal large B-cell lymphoma. Consider participating in clinical trials, as they may provide access to cutting-edge treatments. You can find relevant clinical trials at ClinicalTrials.gov. For additional support, you may explore resources such as the Genetic and Rare Diseases Information Center at rarediseases.info.nih.gov, which can provide guidance on available options and potential registries.
There are currently 85 active clinical trials investigating various aspects of primary mediastinal large B-cell lymphoma. Among the drugs designated for this condition, axicabtagene ciloleucel, lisocabtagene maraleucel, and pembrolizumab have received FDA approval, while nivolumab is still in development. For more information on ongoing trials, you can visit ClinicalTrials.gov and search for primary mediastinal large B-cell lymphoma.
Actionable guidance for navigating care for primary mediastinal large B-cell lymphoma
To navigate your care effectively, seek out a hematologist or oncologist with specific experience in lymphomas, particularly those specializing in primary mediastinal large B-cell lymphoma. Consider participating in clinical trials, as they may provide access to cutting-edge treatments. You can find relevant clinical trials at ClinicalTrials.gov. For additional support, you may explore resources such as the Genetic and Rare Diseases Information Center at rarediseases.info.nih.gov, which can provide guidance on available options and potential registries.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding primary mediastinal large B-cell lymphoma is largely due to its rarity, affecting fewer than 10 individuals per 100,000. This low prevalence restricts the number of systematic clinical studies and comprehensive data collection. Additionally, the lack of established genetic factors and inheritance patterns complicates the understanding of the disease, contributing to the gaps in clinical knowledge.
To navigate your care effectively, seek out a hematologist or oncologist with specific experience in lymphomas, particularly those specializing in primary mediastinal large B-cell lymphoma. Consider participating in clinical trials, as they may provide access to cutting-edge treatments. You can find relevant clinical trials at ClinicalTrials.gov. For additional support, you may explore resources such as the Genetic and Rare Diseases Information Center at rarediseases.info.nih.gov, which can provide guidance on available options and potential registries.
There are currently 85 active clinical trials investigating various aspects of primary mediastinal large B-cell lymphoma. Among the drugs designated for this condition, axicabtagene ciloleucel, lisocabtagene maraleucel, and pembrolizumab have received FDA approval, while nivolumab is still in development. For more information on ongoing trials, you can visit ClinicalTrials.gov and search for primary mediastinal large B-cell lymphoma.
Actionable guidance for navigating care for primary mediastinal large B-cell lymphoma
To navigate your care effectively, seek out a hematologist or oncologist with specific experience in lymphomas, particularly those specializing in primary mediastinal large B-cell lymphoma. Consider participating in clinical trials, as they may provide access to cutting-edge treatments. You can find relevant clinical trials at ClinicalTrials.gov. For additional support, you may explore resources such as the Genetic and Rare Diseases Information Center at rarediseases.info.nih.gov, which can provide guidance on available options and potential registries.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 4 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.